Clinical and microbiologic characteristics of clostridium difficile infection caused by binary toxin producing strain in Korea

Infection and Chemotherapy

Volumn 45, Issue 2, 2013, Pages 175-183

  Kim, Jieun ^a   Seo, Mi Ran ^a   Kang, Jung Oak ^a   Choi, Tae Yeal ^a   Pai, Hyunjoo ^a  

^a Hanyang University College of Medicine   (South Korea)

Author keywords

Binary toxin; Clinical characteristics; Clostridium difficile; PCR ribotype; Susceptibility

Indexed keywords

BINARY TOXIN; CEPHALOSPORIN DERIVATIVE; CLINDAMYCIN; GLYCOPEPTIDE; METRONIDAZOLE; MOXIFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; PROBIOTIC AGENT; RIFAXIMIN; TOXIN; UNCLASSIFIED DRUG; VANCOMYCIN;

ADULT; AGED; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; DISEASE SEVERITY; FATALITY; FECES; FEMALE; HUMAN; KOREA; LEUKOCYTOSIS; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; RIBOTYPING; RISK FACTOR; TREATMENT OUTCOME;

EID: 84884254755     PISSN: 20932340     EISSN: 20926448     Source Type: Journal    
DOI: 10.3947/ic.2013.45.2.175     Document Type: Article

References (29)

1. Hubert B, Loo VG, Bourgault AM, Poirier L, Dascal A, Fortin E, Dionne M, Lorange M. A portrait of the geographic dissemination of the Clostridium difficile North American pulsed-field type 1 strain and the epidemiology of C. difficile-associated disease in Québec.Clin Infect Dis 2007;44:238-44.
2. Cheknis AK, Sambol SP, Davidson DM, Nagaro KJ, Mancini MC, Hidalgo-Arroyo GA, Brazier JS, Johnson S, Gerding DN. Distribution of Clostridium difficile strains from a North American, European and Australian trial of treatment for C. difficile infections: 2005-2007. Anaerobe 2009;15:230-3.
3. Kim J, Kang JO, Kim H, Seo MR, Choi TY, Pai H, Kuijper EJ, Sanders I, Fawley W. Epidemiology of Clostridium difficile infections in a tertiary-care hospital in Korea. Clin Microbiol Infect 2012;21:1469-0691.
4. Kim H, Jeong SH, Roh KH, Hong SG, Kim JW, Shin MG, Kim MN, Shin HB, Uh Y, Lee H, Lee K. Investigation oftoxin gene diversity, molecular epidemiology, and antimicrobial resistance of Clostridium difficile isolated from 12 hospitals in South Korea. Korean J Lab Med 2010; 30:491-7.
5. Carroll KC, Bartlett JG. Biology of Clostridium difficile: implications for epidemiology and diagnosis. Annu Rev Microbiol 2011;65:501-21.
6. Geric B, Carman RJ, Rupnik M, Genheimer CW, Sambol SP, Lyerly DM, Gerding DN, Johnson S. Binary toxin-producing, large clostridial toxin-negative Clostridium difficile strains are enterotoxic but do not cause disease in hamsters. J Infect Dis 2006;193:1143-50.
7. Schwan C, Stecher B, Tzivelekidis T, van Ham M, Rohde M, Hardt WD, Wehland J, Aktories K. Clostridium difficile toxin CDT induces formation of microtubule-based protrusions and increases adherence of bacteria. PLoS Pathog 2009;5:e1000626.
8. Kelly CP, LaMont JT. Clostridium difficile--more difficult than ever. N Engl J Med 2008;359:1932-40.
9. Warny M, Pepin J, Fang A, Killgore G, Thompson A, Brazier J, Frost E, McDonald LC. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 2005;366:1079-84.
10. McDonald LC, Killgore GE, Thompson A, Owens RC Jr, Kazakova SV, Sambol SP, Johnson S, Gerding DN. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 2005;353:2433-41.
11. Tae CH, Jung SA, Song HJ, Kim SE, Choi HJ, Lee M, Hwang Y, Kim H, Lee K. The first case of antibiotic-associated colitis by Clostridium difficile PCR ribotype 027 in Korea. J Korean Med Sci 2009;24:520-4.
12. Kim J, Pai H, Seo MR, Kang JO. Epidemiology and clinical characteristics of Clostridium difficile infection in a Korean tertiary hospital. J Korean Med Sci 2011;26:1258-64.
13. Ferguson MK. The rationale for developing scoring systems for clinical practice. Thorac Surg Clin 2007;17:343-51.
14. Anonymous. World Health Organisation. The anatomical therapeutic chemical (ATC) and defined daily dosing (DDD) system index 2010. Available at: http://www. whocc.no/. Accessed 28 October 2010.
15. Zar FA, Bakkanagari SR, Moorthi KM, Davis MB. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 2007;45:302-7.
16. Gerding DN, Muto CA, Owens RC Jr. Treatment of Clostridium difficile infection. Clin Infect Dis 2008;46 (Suppl 1):S32-42.
17. Cheong HS, Kim JK, Lim TK, Kwon KT, Ryu SY, Heo ST, Ko KS, Oh WS, Peck KR, Lee NY, Song JH. Therapeutic efficacy of metronidazole for patients with Clostridium difficile-associated diarrhea. Korean J Med 2007;72:639- 46.
18. Barbut F, Richard A, Hamadi K, Chomette V, Burghoffer B, Petit JC. Epidemiology of recurrences or reinfections of Clostridium difficile-associated diarrhea. J Clin Microbiol 2000;38:2386-8.
19. Seo MR, Kim J, Kang JO, Choi TY, Pai H. Multiplex PCR method for detection of Clostridium difficile tcdA, tcdB and binary toxin genes. 2012 Annual Meeting of the Korean Society of Infectious Disease and the Korean Society for Chemotherapy: 2012 Sep 1-2; Jeju, Korea. p. 179.
20. Kim J, Kang JO, Pai H, Choi TY. Association between PCR ribotypes and antimicrobial susceptibility among Clostridium difficile isolates from healthcare-associated infections in South Korea. Int J Antimicrob Agents 2012;40:24-9.
21. Kim H, Lee Y, Moon HW, Lim CS, Lee K, Chong Y. Emergence of Clostridium difficile Ribotype 027 in Korea. Korean J Lab Med 2011;31:191-6.
22. Bauer MP, Notermans DW, van Benthem BH, Brazier JS, Wilcox MH, Rupnik M, Monnet DL, van Dissel JT, Kuijper EJ; ECDIS Study Group. Clostridium difficile infection in Europe: a hospital-based survey. Lancet 2011;377:63-73.
23. Bacci S, MØlbak K, Kjeldsen MK, Olsen KE. Binary toxin and death after Clostridium difficile infection. Emerg Infect Dis 2011;17:976-82.
24. Barbut F, Decré D, Lalande V, Burghoffer B, Noussair L, Gigandon A, Espinasse F, Raskine L, Robert J, Mangeol A, Branger C, Petit JC. Clinical features of Clostridium difficile- associated diarrhoea due to binary toxin (actin-specific ADP-ribosyltransferase)-producing strains. J Med Microbiol 2005;54:181-5.
25. Barbut F, Gariazzo B, Bonné L, Lalande V, Burghoffer B, Luiuz R, Petit JC. Clinical features of Clostridium difficile- associated infections and molecular characterization of strains: results of a retrospective study, 2000- 2004. Infect Control Hosp Epidemiol 2007;28:131-9.
26. Walk ST, Micic D, Jain R, Lo ES, Trivedi I, Liu EW, Almassalha LM, Ewing SA, Ring C, Galecki AT, Rogers MA, Washer L, Newton DW, Malani PN, Young VB, Aronoff DM. Clostridium difficile ribotype does not predict severe infection. Clin Infect Dis 2012;55:1661-8.
27. Jobe BA, Grasley A, Deveney KE, Deveney CW, Sheppard BC. Clostridium difficile colitis: an increasing hospital- acquired illness. Am J Surg 1995;169:480-3.
28. Lyytikäinen O, Turunen H, Sund R, Rasinperä M, Könönen E, Ruutu P, Keskimäki I. Hospitalizations and deaths associated with Clostridium difficile infection, Finland, 1996-2004. Emerg Infect Dis 2009;15:761-5.
29. Rubin MS, Bodenstein LE, Kent KC. Severe Clostridium difficile colitis. Dis Colon Rectum 1995;38:350-4.